October 5, 2026 · Patent expires June 14, 2027

Rexulti (Brexpiprazole): The 2027-2032 Generic Opportunity Window

Otsuka and Lundbeck's blockbuster atypical antipsychotic Rexulti (brexpiprazole) generated over $2.0 billion globally in 2024, with U.S. net sales exceeding $1.7 billion. Core substance patent US 7,888,362 expires in December 2026 (extended to June 14, 2027 via pediatric exclusivity), opening a high-value generic transition window through 2032 for Paragraph IV challengers including Zydus Lifesciences, Torrent, Alembic, MSN Laboratories, and Dr. Reddy's.

What we do

We track expirations like this continuously

This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.